Rocket Pharmaceuticals Inc’s recently made public that its Former Officer White Mark Andrew acquired Company’s shares for reported $30943.0 on Jan 31 ’25. In the deal valued at $10.96 per share,2,824 shares were bought.
Then, Militello John sold 896 shares, generating $9,300 in total proceeds. Upon selling the shares at $10.38, the insider now owns 48,414 shares.
Before that, Militello John bought 896 shares. Rocket Pharmaceuticals Inc shares valued at $9,301 were divested by the Officer at a price of $10.38 per share.
Wedbush initiated its Rocket Pharmaceuticals Inc [RCKT] rating to an Outperform in a research note published on December 30, 2024; the price target was $32. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. Scotiabank began covering RCKT with “Sector outperform” recommendation on October 16, 2024. Goldman started covering the stock on April 02, 2024. It rated RCKT as “a Neutral”.
Price Performance Review of RCKT
On Tuesday, Rocket Pharmaceuticals Inc [NASDAQ:RCKT] saw its stock jump 3.15% to $10.80. Over the last five days, the stock has gained 6.82%. Rocket Pharmaceuticals Inc shares have fallen nearly -14.08% since the year began. Nevertheless, the stocks have fallen -62.63% over the past one year. While a 52-week high of $31.47 was reached on 01/02/25, a 52-week low of $9.33 was recorded on 02/12/25. SMA at 50 days reached $11.44, while 200 days put it at $17.65.
Levels Of Support And Resistance For RCKT Stock
The 24-hour chart illustrates a support level at 10.48, which if violated will result in even more drops to 10.17. On the upside, there is a resistance level at 11.11. A further resistance level may holdings at 11.43. The Relative Strength Index (RSI) on the 14-day chart is 49.71, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.03, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 30.66%. Stochastics %K at 58.96% indicates the stock is a holding.
The most recent change occurred on October 24, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $65 price target.
